

Elisa Mandato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5957529/publications.pdf>

Version: 2024-02-01

12
papers

390
citations

1040056

9
h-index

1474206

9
g-index

12
all docs

12
docs citations

12
times ranked

853
citing authors

#	ARTICLE	IF	CITATIONS
1	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.	30.7	87
2	Targeted inhibition of PI3K $\hat{\pm}$ /I $\hat{\nu}$ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. <i>Blood</i> , 2019, 133, 70-80.	1.4	75
3	Protein Kinase CK2 Inhibition Down Modulates the NF- $\hat{\nu}$ B and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. <i>PLoS ONE</i> , 2013, 8, e75280.	2.5	75
4	Protein kinase CK2 regulates AKT, NF- $\hat{\nu}$ B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 292-300.	7.2	55
5	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015, 6, 6544-6552.	1.8	31
6	Targeting CK2-driven non-oncogene addiction in B-cell tumors. <i>Oncogene</i> , 2016, 35, 6045-6052.	5.9	24
7	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 20.	6.2	19
8	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. <i>Leukemia</i> , 2014, 28, 2094-2097.	7.2	14
9	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. <i>Current Cancer Drug Targets</i> , 2018, 18, 608-616.	1.6	10
10	Targeted Inhibition of PI3K $\hat{\pm}$ /I $\hat{\nu}$ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL. <i>Blood</i> , 2018, 132, 39-39.	1.4	0
11	MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8. <i>Blood</i> , 2021, 138, 1324-1324.	1.4	0
12	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 713-713.	1.4	0